Taken together, the data suggest that NK-cell function is preserved in patients undergoing chemotherapy, that NPC tumors cells exposed to chemotherapeutics show increased sensitivity to NK-cell killing and that the degree of this killing can be augmented by the addition of an anti-PD-1 antibody during chemotherapy. Here, PDCD1 is linked to nasopharyngeal carcinoma.